<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585113</url>
  </required_header>
  <id_info>
    <org_study_id>DAD2020</org_study_id>
    <nct_id>NCT04585113</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of Dual-energy CT</brief_title>
  <acronym>DAD</acronym>
  <official_title>Diagnostic Value of Dual-energy CT to Detect and Characterize Crystal Deposits in Patients With Hand Osteoarthritis Undergoing Hand Surgery: a Diagnostic Accuracy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bliddal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Frederiksberg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include 20 people with hand OA awaiting surgery in the fingers. Participants&#xD;
      will undergo dual-energy CT, cone-beam CT, ultrasound, clinical examination, blood sampling&#xD;
      and questionnaires. Images will be analysed for the presence of joint-associated crystal&#xD;
      including monosodium urate, calcium pyrophosphate and calcium hydroxyapatite. Material&#xD;
      obtained during surgery will be used for crystal verification and calculation of diagnostic&#xD;
      accuracy of dual-energy CT and cone-beam CT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive likelihood ratio</measure>
    <time_frame>20 months</time_frame>
    <description>To determine the positive likelihood ratio of DECT to detect crystal deposition in an osteoarthritic joint of the hand.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discriminating joint-associated crystals</measure>
    <time_frame>20 months</time_frame>
    <description>To determine DECTs ability to discriminate MSU from calcium-containing crystals in an osteoarthritic joint of the hand.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative likelihood ratio</measure>
    <time_frame>20 months</time_frame>
    <description>To determine the negative likelihood ratio of DECT to detect crystal deposition in an osteoarthritic joint of the hand.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>20 months</time_frame>
    <description>Synovitis-score of inflammation detected by ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between inflammation and crystals</measure>
    <time_frame>20 months</time_frame>
    <description>Analysis of covariance (ANCOVA), with a factor for presence of crystals (X=1 or X=0), and synovitis score as dependent variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degenerative status</measure>
    <time_frame>20 months</time_frame>
    <description>Described by KL-score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between KL-score and crystals</measure>
    <time_frame>20 months</time_frame>
    <description>Analysis of covariance (ANCOVA), with a factor for presence of crystals (X=1 or X=0), and KL-score as dependent variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erosions score</measure>
    <time_frame>20 months</time_frame>
    <description>Erosions as estimated by the hand osteoarthritis magnetic resonance imaging scoring system (HOAMRIS) for erosions evaluated by CBCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between erosion-score and crystals</measure>
    <time_frame>20 months</time_frame>
    <description>Analysis of covariance (ANCOVA), with a factor for presence of crystals (X=1 or X=0), and erosion-score as dependent variable.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Hand Osteoarthritis</condition>
  <condition>Crystal; Deposit Joint</condition>
  <condition>Crystals; Arthritis, Pyrophosphate</condition>
  <condition>Crystals; Arthritis, Hydroxyapatite</condition>
  <condition>Crystal Arthritis</condition>
  <condition>Crystal Arthropathy of Hand</condition>
  <arm_group>
    <arm_group_label>People with hand OA awaiting surgery</arm_group_label>
    <description>Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible. All IP joints in the hands are eligible (thus both IP, PIP and DIP) if in- and exclusion criteria are fulfilled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT-scanning</intervention_name>
    <description>All participants will receive dual-energy CT scanning and cone-beam CT scanning prior surgery.</description>
    <arm_group_label>People with hand OA awaiting surgery</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Material obtained during surgery from the joint.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hand OA awaiting hand surgery of a joint with OA will be considered eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Informed consent obtained.&#xD;
&#xD;
          3. Patients with hand OA as defined by the American College of Rheumatology&#xD;
             Classification Criteria for hand OA:&#xD;
&#xD;
               -  Hand pain, aching or stiffness&#xD;
&#xD;
        And 3 or 4 of the following features:&#xD;
&#xD;
          -  Hard tissue enlargement of ≥2 of the 10 selected joints*.&#xD;
&#xD;
          -  Hard tissue enlargement of ≥2 of the 10 DIP joints.&#xD;
&#xD;
          -  Fewer than 3 swollen MCP joints.&#xD;
&#xD;
          -  Deformity of at least 1 of 10 selected joints*. *The 10 selected joints are the second&#xD;
             and third DIP, the second and third PIP, and the first carpometacarpal joints of both&#xD;
             hands.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known inflammatory rheumatic diseases (e.g. rheumatoid arthritis, gout, psoriatic&#xD;
             arthritis, psoriasis, inflammatory bowel disease), or other joint diseases&#xD;
             (haemochromatosis)&#xD;
&#xD;
          2. Positive anti-cyclic citrullinated peptide (&gt;10 kU/L)&#xD;
&#xD;
          3. Known cutaneous deposition diseases (e.g. amyloidosis or porphyria).&#xD;
&#xD;
          4. Foreign material/metallic implants at the area of interest will be excluded to avoid&#xD;
             artefacts on CBCT [68].&#xD;
&#xD;
          5. Other diseases in the area - e.g. skin disease, known previous fracture in the joint&#xD;
             of interest.&#xD;
&#xD;
          6. Participation in experimental device or experimental drug study 3 months prior to&#xD;
             enrolment.&#xD;
&#xD;
          7. Pregnancy or breast-feeding.&#xD;
&#xD;
          8. Previous septic arthritis at the target joint.&#xD;
&#xD;
          9. Previous surgical procedures at the target joint.&#xD;
&#xD;
         10. Injection into the target joint within 3 months prior to enrolment.&#xD;
&#xD;
         11. Inability to speak and read Danish fluently.&#xD;
&#xD;
         12. Treatment with Colchicine within the last 30 days.&#xD;
&#xD;
         13. Treatment with systemic steroids ≥7.5 mg prednisolone within the last 30 days.&#xD;
&#xD;
         14. Lack of sample obtained for reference standard, i.e. unable to obtain either synovial&#xD;
             fluid, joint lavage fluid, joint biopsy or excite joint.&#xD;
&#xD;
         15. Any other condition that in the opinion of the investigator may interfere with study&#xD;
             participation.&#xD;
&#xD;
        There will be no restriction on sex or Kellgren-Lawrence (KL) grading.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bliddal, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parker Instituttet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Døssing, MD</last_name>
    <phone>+45 38164153</phone>
    <email>anna.dossing@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Parker Institute, Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>DK</state>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Døssing, MD</last_name>
      <phone>38164153</phone>
      <email>anna.dossing@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Frederiksberg University Hospital</investigator_affiliation>
    <investigator_full_name>Henning Bliddal</investigator_full_name>
    <investigator_title>MD, DMSci, Professor of Rheumatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Crystal Arthropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

